Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Multiple Sclerosis Clinical Trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (16) clinical trials

Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment

Umbilical cord derived MSCs bank will be generated and all patients given the same cells from the same biological sample. Thorough clinical, cognitive and motor analysis will be performed at baseline and compared to outcomes at 3 different time points of all enrolled patients. The study will consist of three ...

Phase

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

STUDY TREATMENT: Investigational therapy product: Wharton Jelly derived allogeneic MSCs. Method of administration and dose: Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI). SAFETY ...

Phase

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

STUDY TREATMENT: Investigational therapy product: Autologous Bone Marrow-Derived Mesenchymal Stem Cells (BM-MNC). Method of administration and dose: Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI). SAFETY ...

Phase

Efficacy Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS

1. Evaluate the clinical efficacy of andrographolide 140 mg administered orally twice a day versus a placebo in: - Delay in the disability capacity progression through the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) at 24 months compared to the baseline. - Delay in cognitive impairment ...

Phase

T-Cell Vaccination in Multiple Sclerosis (MS)

Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones. Clinical immunologic and neuroradiologic evaluation.

Phase

MitoQ for Fatigue in Multiple Sclerosis

MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. While the cause of MS related fatigue is uncertain, the investigators believe that mitochondria dysfunction and resultant neuronal energy depletion may be an important contributor to fatigue in MS. This clinical trial will evaluate the potential ...

Phase

Safety and Tolerability of Quetiapine in Multiple Sclerosis

Background Multiple sclerosis causes episodes of inflammation that injure or kill nerve cells and the cells that coat them with myelin. These episodes of inflammation may cause a relapse (attack) or the inflammation may only be detectable with brain MRI. Inflammatory episodes are the main feature of relapsing-remitting MS (RRMS). ...

Phase

Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease

Four groups of subjects will be recruited: Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, or at least one gadolinium enhancing lesion on Magnetic Resonance Imaging (MRI) within 3 months of ...

Phase

Mesenchymal Cells From Autologous Bone Marrow Administered Intravenously in Patients Diagnosed With Multiple Sclerosis

The study population will consist of a total of 30 patients diagnosed with multiple sclerosis, who meet all inclusion criteria and none of the exclusion set and express their agreement to participate in the study by signing the informed consent of those whose results can be clinically evaluable. Selected patients ...

Phase

Targeting Residual Activity By Precision Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Objective Multiple inflammatory and neurodegenerative mechanisms drive progression of disability in fully established multiple sclerosis (MS); therefore, it is unlikely that a single therapeutic agent will be curative. Analogous to cardiovascular diseases, effective treatments for evolved MS will likely require individualized combination therapies that target pathogenic processes active in the ...

Phase